Estradiol: A Steroid with Multiple Facets

Abstract

Seventy-five glorious years have passed since estradiol was discovered by Edward Doisy. From discovery in the ovaries to delineation of diverse physiological effects, research on estrogens has covered a lot of ground. Estrogen receptors that mediate estrogenic effects, have been detected not only in reproductive organs, but also in other body organs. Estrogen receptors function either as conventional transcription factors or as rapid signal transducers. These different modes of action are opted by estrogens to elicit an array of reproductive and non-reproductive functions. It is well established that estrogens promote cell proliferation in various tissues and hence are also linked to carcinogenesis. Anti-estrogens are being used as adjunct therapies for cancers since several years. On the other hand, estrogen-based strategies are used to alleviate adverse effects of menopause. Apart from estrogens synthesized in various organs, exposure to environmental estrogens can also impact physiology. Thus, too much or too less of estrogens can tip the balance and lead to unfavorable consequences. Multiple estrogen receptors with their tissue- or cell type-specific expression eliciting dose-dependent effects make it perplexing to ‘unify’ estrogenic actions in diverse tissues/organs. This warrants more research on estrogen-mediated effects and their regulation in somatic and reproductive tissues. This review presents physiological and pathological aspects of estrogens thus highlighting the good, bad, and ugly facets of estrogens.

Key words

hormone - physiology - menopause - carcinogenesis - environmental estrogens

• References

• 1 Allen E, Doisy EA. An ovarian hormone: Preliminary report on its localization, extraction and partial purification, and action in test animals. J Am Med Assoc 1923; 81: 819-821
• 2 Veler CD, Thayer S, Doisy EA. The preparation of the crystalline follicular ovarian hormone: Theelin. J Biol Chem 1930; 87: 357-371
• 3 Huffman MN, Thayer SA, Doisy EA. The isolation of α-dihydrotheelin from human placenta. J Biol Chem 1940; 133: 567-571
• 4 Butenandt A. Uber Progynon ein krytallisiertes weibliches Sexualhormon. Die Naturwissenschaften 1929; 17: 879
• 5 Simpson E, Santen RJ. Celebrating 75 years of oestradiol. J Mol Endocrinol 2015; 55: T1-T20
• 6 Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009; 457: 219-223
• 7 Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M. Aromatase – a brief overview. Annu Rev Physiol 2002; 64: 93-127
• 8 Meyer AS. Conversion of 19-hydroxy-delta 4-androstene-3,17-dioneto oestradiol by endocrine tissue. Biochim Biophys Acta 1955; 17: 441-442
• 9 Morato T, Hayano M, Dorfman RI, Axelrod LR. The intermediate steps in the biosynthesis of oestrogen from androgens. Biochem Biophys Res Commun 1961; 6: 334-338
• 10 Steinach E, Kun H. Transformation of male sex hormones into a substance with the action of a female hormone. Lancet 1937; 30: 845
• 11 Jensen EV, Suzuki T, Kawashima T, Stumpf WE, Jungblut PW, DeSombre ER. A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci U S A 1968; 59: 632-638
• 12 Walter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 1985; 82: 7889-7893
• 13 Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-5930
• 14 Gosden JR, Middleton PG, Rout D. Localization of the human oestrogen receptor gene to chromosome 6q24-q27 by in situ hybridization. Cytogenet Genome Res 1986; 43: 43218-43220
• 15 Enmark E, Pelto-Huikko M, Grandien KA, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M, Gustafsson JA. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258-4265
• 16 Mosselman S, Polman J, Dijkema R. ERβ: Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53
• 17 Al-Bader M, Ford C, Al-Ayadhy B, Francis I. Analysis of estrogen receptor isoforms and variants in breast cancer cell lines. Exp Ther Med 2011; 2: 537-544
• 18 Poola I, Koduri S, Chatra S, Clarke R. Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach. J Steroid Biochem Mol Biol 2000; 72: 249-258
• 19 Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, Gannon F. Identification of a new isoform of the human estrogen receptor-alpha (hER-α) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1. EMBO J 2000; 19: 4688-4700
• 20 Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66. Biochem Biophys Res Commun 2005; 336: 1023-1027
• 21 Pink JJ, Wu SQ, Wolf DM, Bilimoria MM, Jordan VC. A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res 1996; 24: 962-969
• 22 Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM. Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun 1998; 247: 75-78
• 23 Ogawa S, Eng V, Taylor J, Lubahn DB, Korach KS, Pfaff DW. Roles of Estrogen Receptor-α Gene Expression in Reproduction-Related Behaviors in Female Mice. Endocrinology 1998; 139: 5070-5081
• 24 Zhao C, Matthews J, Tujague M, Wan J, Ström A, Toresson G, Lam EW, Cheng G, Gustafsson JÅ, Dahlman-Wright K. Estrogen receptor β2 negatively regulates the transactivation of estrogen receptor α in human breast cancer cells. Cancer Res 2007; 67: 3955-3962
• 25 Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-β isoforms: a key to understanding ER-β signaling. Proc Natl Acad Sci USA 2006; 103: 13162-13167
• 26 O'Malley BW. In vitro hormonal induction of a specific protein (avidin) in chick oviduct. Biochem 1967; 6: 2546-2551
• 27 Kumar V, Green S, Staub A, Chambon P. Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor. EMBO 1986; 5: 2231-2236
• 28 Klein-Hitpass L, Tsai SY, Greene GL, Clark JH, Tsai MJ, O'Malley BW. Specific binding of estrogen receptor to the estrogen response element. Mol Cell Biol 1989; 9: 43-49
• 29 Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH, Mader S. Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mole Endocrinol 2004; 18: 1411-1427
• 30 Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000; 74: 311-317
• 31 Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW. An essential role for ectodomain shedding in mammalian development. Science 1998; 282: 1281-1284
• 32 Kim SM, Rhee JH. A case of 17 alpha-hydroxylase deficiency. Clin Expt Reprod Med 2015; 42: 72-76
• 33 Prokai L, Simpkins JW. Structure–nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds. Pharmacol Ther 2007; 114: 1-2
• 34 Watsona CS, Norfleet AM, Pappas TC, Gametchu B. Rapid actions of estrogens in GH 3/B6 pituitary tumor cells via a plasma membrane version of estrogen receptor-α. Steroids 1999; 64: 5-13
• 35 Simpkins JW, Yang SH, Sarkar SN, Pearce V. Estrogen actions on mitochondria—physiological and pathological implications. Mol Cell Endocrinol 2008; 290: 51-59
• 36 Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 2011; 7: 715-726
• 37 Luconi M, Muratori M, Forti G, Baldi E. Identification and characterization of a novel functional estrogen receptor on human sperm membrane that interferes with progesterone effects. J Clin Endocrinol Metabol 1999; 84: 1670-1678
• 38 Pedram A, Razandi M, Lewis M, Hammes S, Levin ER. Membrane-localized estrogen receptor α is required for normal organ development and function. Dev cell 2014; 9: 482-490
• 39 Milner TA, Ayoola K, Drake CT, Herrick SP, Tabori NE, McEwen BS, Warrier S, Alves SE. Ultrastructural localization of estrogen receptor beta immunoreactivity in the rat hippocampal formation. J Comp Neurol 2005; 491: 81-95
• 40 Brady TK, McDonald F, Odendal M. The localization of estrogen receptors on human osteoblasts: A preliminary optical and electron microscopic technique. Cell Biochem Biophys 2004; 40: 237-247
• 41 Moats II RK, Ramirez VD. Electron microscopic visualization of membrane-mediated uptake and translocation of estrogen–BSA: Colloidal gold by Hep G2 cells. J Endocrinol 2000; 166: 631-647
• 42 Singh S, Shaul PW, Gupta PW. Conventional estrogen receptors are found in the plasma membrane of vaginal epithelial cells of the rat. Steroids 2002; 67: 757-764
• 43 Powell CE, Soto AM, Sonnenschein C. Identification and characterization of membrane estrogen receptor from MCF7 estrogen-target cells. J Steroid Biochem Mol Biol 2001; 77: 97-108
• 44 Pedram A, Razandi M, Evinger AJ, Lee E, Levin ER. Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. Mol Biol Cell 2009; 20: 3374-3389
• 45 Acconcia F, Bocedi A, Ascenzi P, Marino M. Does Palmitoylation Target Estrogen Receptors to Plasma Membrane Caveolae?. IUBMB Life 2003; 55: 33-35
• 46 Acconcia F, Marino M. The effects of 17β-estradiol in cancer are mediated by estrogen receptor signaling at the plasma membrane. Front Physiol 2011; 2: 30
• 47 Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, Collinge M, Sessa WC, Bender JR. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. Biol Chem 2003; 278: 2118-2123
• 48 Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY. A positive feedback loop of ER-a36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 2011; 30: 770-780
• 49 Chaudhri RA, Olivares-Navarrete R, Cuenca N, Hadadi A, Boyan BD, Schwartz Z. Membrane Estrogen Signaling Enhances Tumorigenesis and Metastatic Potential of Breast Cancer Cells via Estrogen Receptor-α36 (ERα36). J Biol Chem 2012; 287: 7169-7181
• 50 Haas E, Bhattacharya I, Brailoiu E, Damjanović M, Brailoiu GC, Gao X, Mueller-Guerre L, Marjon NA, Gut A, Minotti R, Meyer MR. Regulatory role of G protein–coupled estrogen receptor for vascular function and obesity. Circulation Res 2009; 104: 288-291
• 51 Feng Y, Gregor P. Cloning of a novel member of the G protein-coupled receptor family related to peptide receptors. Biochem Biophys Res Commun 1997; 231: 651-654
• 52 Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-1630
• 53 Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, Thomas P. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinol 2007; 148: 3236-3245
• 54 Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prelle K, Nubbemeyer R, Fritzemeier KH. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinol 2008; 149: 4846-4856
• 55 Knobil E, Neill JD. Knobil and Neill's Physiology of Reproduction Vol. 2. Neil JD. (ed) Houston, TX: Gulf Professional Publishing; 2006
• 56 Rosenfeld CS, Wagner JS, Roberts RM, Lubahn DB. Intraovarian actions of oestrogen. Reproduction 2001; 122: 215-226
• 57 Drummond AE. The role of steroids in follicular growth. Reprod Biol Endocrinol 2006; 4: 16
• 58 Groothuis PG, Dassen HHNM, Romano A, Punyadeera C. Estrogen & the endometrium: Lessons learned from gene expression profiling in rodents and human. Hum Reprod Update 2007; 13: 405-417
• 59 Paulson RJ. Hormonal induction of endometrial receptivity. Fertil Steril 2011; 96: 530-535
• 60 Shyamala G. Roles of estrogen and progesterone in normal mammary gland development: Insights from progesterone receptor null mutant mice & in situ localization of receptor. Trends Endocrinol Metab 1997; 8: 34-39
• 61 Clarke IJ, Campbell R, Smith JT, Prevot V, Wray S. Neuroendocrine control of reproduction. In: Fink G, Pfaff DW, Levine JE. (eds) Handbook of Neuroendocrinology. Amsterdam: Elsevier; 2012: 197-236
• 62 Wolff E. Sur la transformation des Poulets males en intersexues par injection d'hormone femelle (folliculine) aux embryons. Archiv Anat Histol Embryol 1935; 20: 219-278
• 63 McLachlan JA, Newbold RR, Bullock B. Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. Science 1975; 190: 991-992
• 64 Tsai-Morris CH, Aquilano DR, Dufau ML. Cellular localization of rat testicular aromatase activity during development. Endocrinology 1985; 116: 38-46
• 65 Nitta H, Bunick D, Hess RA, Janulis L, Newton SC, Millette CF, Osawa Y, Shizuta Y, Toda K, Bahr JM. Germ cells of the mouse testis express P450 aromatase. Endocrinology 1993; 132: 1396-1401
• 66 Carreau S, Genissel C, Bilinska B, Levallet J. Topical review: Sources of oestrogen in the testis & reproductive tract of the male. J Androl 1999; 22: 211-223
• 67 Korach KS, Couse JF, Curtis SW, Washburn TF, Lindzey J, Kimbro KS, Eddy EM, Migliaccio S, Snedeker SM, Lubahn DB, Schomberg DW, Smith EP. Estrogen receptor gene disruption: molecular characterization & experimental & clinical phenotypes. Recent Prog Horm Res 1995; 51: 159-186
• 68 Antal MC, Krust A, Chambon P, Mark M. Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERβ-null mutant. Proc Natl Acad Sci U S A 2008; 105: 2433-2438
• 69 Robaire B, Duron J, Hales BF. Effect of estradiol-filled polydimethylsiloxane subdermal implants in adult male rats on the reproductive system, fertility, and progeny outcome. Biol Reprod 1987; 37: 327-334
• 70 Gill-Sharma MK, D'souza S, Padwal V, Balasinor N, Aleem M, Parte P. Antifertility effects of estradiol in adult male rats1. J Endocrinol Invest 2001; 24: 598-607
• 71 O’Donnell L, Meachem SJ, Stanton PG, McLachlan RI. Endocrine regulation of spermatogenesis. In: Knobil and Neill’s Physiology of Reproduction. Neill JD. (ed) Houston TX: Gulf Professional Publishing; 2006. 1 1017-1070
• 72 Schlegel PN. Aromatase inhibitors for male infertility. Fertil Steril 2012; 98: 1359-1362
• 73 Dumasia K, Kumar A, Deshpande S, Sonawane S, Balasinor NH. Differential roles of estrogen receptors, ESR1 and ESR2, in adult rat spermatogenesis. Mol Cell Endocrinol 2016; 428: 89-100
• 74 Kumar A, Dumasia K, Gaonkar R, Sonawane S, Kadam L, Balasinor NH. Estrogen and androgen regulate actin-remodeling and endocytosis-related genes during rat spermiation. Mol Cell Endocrinol 2015; 404: 91-101
• 75 Robaire B, Hinton BT, Orgebin-Crist MC. The epididymis. In: Knobil & Neill's Physiology of Reproduction. Neill JD. ed. Houston, TX: Gulf Professional Publishing; 2006. 1 1071-1148
• 76 Risbridger GP, Ellem SJ, McPherson SJ. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol 2007; 39: 183-188
• 77 Arnold AP, Breedlove SM. Organizational and activational effects of sex steroids on brain and behavior: A reanalysis. Horm Behav 1985; 19: 469-498
• 78 Amateau SK, McCarthy MM. Induction of PGE2 by estradiol mediates developmental masculinization of sex behavior. Nat Neurosci 2004; 7: 643
• 79 Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811
• 80 Brincat MP, Muscat Baron Y, Galea R. Estrogens & the skin. Climacteric 2005; 8: 110-123
• 81 Manolagas SC, O'brien CA, Almeida M. The role of estrogen and androgen receptors in bone health & disease. Nat Rev Endocrinol 2013; 9: 699-712
• 82 Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 2013; 34: 309-338
• 83 López M, Tena-Sempere M. Estrogens and the control of energy homeostasis: a brain perspective. Trends Endocrinol Metab 2015; 26: 411-421
• 84 Jones ME, Boon WC, Proietto J, Simpson ER. Of mice and men: the evolving phenotype of aromatase deficiency. Trends Endocrinol Metab 2006; 17: 55-64
• 85 Zirilli L, Rochira V, Diazzi C, Caffagni G, Carani C. Human models of aromatase deficiency. J Steroid Biochem Mol Biol 2008; 109: 212-218
• 86 Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson ER. Molecular basis of the aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci U S A 1993; 90: 11673-11677
• 87 Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997; 337: 91-95
• 88 Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H. Aromatase deficiency in a female who is compound heterozygote for new point mutations in the P450arom gene: impact of estrogens on hypergonadotropichypogonadism, multicystic ovaries, & bone densitometry in childhood. J Clin Endocrinol Metab 1997; 82: 1739-1745
• 89 Lin L, Eran O, Raza J, Burren CP, Creighton SM, Auchus RJ, Dattani MT, Acherman JC. Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. J Clin Endocrinol Metab 2007; 92: 982-990
• 90 Kim SM, Rhee JH. A case of 17 alpha-hydroxylase deficiency. Clin Exp Reprod Med 2015; 42: 72-76
• 91 Smith EP, Boyd J, Frank GR, Takahashi H, Cohen R.M, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056-1061
• 92 Quaynor SD, Stradtman Jr. EW, Kim H.G, Shen Y, Chorich LP, Schreihofer DA, Layman LC. Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant. N Engl J Med 2013; 369: 164-171
• 93 Mckinlay SM. The normal menopause transition: an overview. Maturitas 1996; 23: 137-145
• 94 Makara-Studzińśka MT, Kryś-Noszczyk KM, Jakiel G. Epidemiology of the symptoms of menopause–an intercontinental review. Menopause Rev 2014; 13: 203
• 95 Woodruff JD, Pickar JH. Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170: 1213-1223
• 96 Kling J. The strange case of Premarin. Mod Drug Discov 2000; 3: 46-52
• 97 Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-333
• 98 Klaiber EL, Vogel W, Rako S. A critique of the Women’s Health Initiative hormone therapy study. Fertil Steril 2005; 84: 1589-1601
• 99 Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA. Postmenopausal hormone therapy: An Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95 7 Supp 1 s1-s66
• 100 Whayne Jr. TF, Mukherjee D. Women, the menopause, hormone replacement therapy and coronary heart disease. Curr Opin Cardiol 2015; 30: 432-438
• 101 Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT. Prescribing menopausal hormone therapy: an evidence-based approach. Int J Womens Health 2014; 6: 47
• 102 Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Hormone therapy and ovarian cancer: Incidence and survival. Cancer Causes Control 2008; 19: 605-613
• 103 Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol 2014; 142: 83-89
• 104 Yao Y, Gu X, Zhu J, Yuan D, Song Y.. Hormone replacement therapy in females can decrease the risk of lung cancer: A meta-analysis. PLoS One 2013; 8: e71236
• 105 Barzi A, Lenz AM, Labonte MJ, Lenz HJ. Molecular pathways: estrogen pathway in colorectal cancer. Clin Cancer Res 2013; 19: 5842-5848
• 106 Eisenberger A, Westhoff C. Hormone replacement therapy and venous thromboembolism. J Steroid Biochem Mol Biol 2014; 142: 76-82
• 107 Sherwin BB. Estrogen therapy: Is time of initiation critical for neuroprotection?. Nat Rev Endocrinol 2009; 5: 620-607
• 108 Stevenson JC. Type and route of estrogen administration. Climacteric 2009; 12 Supp 1 86-90
• 109 Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clinic Proceed 2011; 86: 673-680
• 110 Fishman JR, Flatt MA, Settersten RA. Bioidentical hormones, menopausal women, and the lure of the “natural” in US anti-aging medicine. Soc Sci Med 2015; 132: 79-87
• 111 Shozu M, Zhao Y, Bulun SE, Simpson ER. Multiple splicing events involved inregulation of human aromatase expression by a novel promoter, 1.6. Endocrinology 1998; 139: 1610-1617
• 112 Shozu M, Sumitani H, Segawa T, Yang HJ, Murakami K, Kasai T, Inoue M. Overexpression of aromatase P450 in leiomyoma tissue is driven primarily through promoter I.4 of the aromatase P450 gene (CYP19). J Clin Endocrinol Metab 2002; 87: 2540-2548
• 113 Ham S, Meachem SJ, Choong CS, Charles AK, Baynam GS, Jones TW, Samarajeewa NU, Simpson ER, Brown KA. Overexpression of aromatase associated with loss of heterozygosity of the STK11 gene accounts for prepubertal gynecomastia in boys with Peutz-Jeghers syndrome. J Clin Endocrinol Metab 2013; 98: E1979-E1987
• 114 Agarwal VR, Takayama K, Van Wyk JJ, Sasano H, Simpson ER, Bulun SE. Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J Clin Endocrinol Metab 1998; 83: 1797-1800
• 115 Bulun SE. Endometriosis. N Engl J Med 2009; 360: 268-279
• 116 Plourde P, Reiter E, Jou H, Desrochers P, Rubin S, Bercu B, Diamond FJ, Backeljauw P. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: A randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004; 44: 28-33
• 117 Shozu M, Murakami K, Segawa T, Kasai T, Inoue M. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril 2003; 79: 628-631
• 118 Ailawadi R, Jobanputra S, Kataria M, Gurates B, Bulun S. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: A pilot study. Fertil Steril 2004; 81: 290-296
• 119 Henderson BE, Ross RK, Pike MC. Toward the primary prevention of cancer. Science 1991; 254: 1131-1138
• 120 Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993; 15: 48-65
• 121 Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, Hennekens CH, Rosner B, Speizer FE, Willett WC. Dual effects of weight and weight gain on breast cancer risk. J Am Med Assoc 1997; 278: 1407-1411
• 122 Frasor J, Danes JM, Komm B, Chang KCN, Richard Lyttle C, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144: 4562-4574
• 123 Foster JS, Henley DC, Ahamed S, Wimalasena J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 2001; 12: 320-327
• 124 Bennin DA, Arachchige Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L, Depaoli-Roach AA, Horne MC. Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B′ subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest. J Biol Chem 2002; 277: 27449-27467
• 125 Bratton MR, Duong BN, Elliott S, Weldon CB, Beckman BS, McLachlan JA, Burow ME. Regulation of ERα-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: Implications for breast cancer cell survival. Int J Oncol 2010; 37: 541-550
• 126 Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002; 80: 239-256
• 127 Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 2002; 21: 4000-4008
• 128 Noruzinia M, Coupier I, Pujol P. Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?. Cancer 2005; 104: 1567-1574
• 129 Xujuan Y, Belosay A, Mengyuan D, Fan TM, Turner RT, Iwaniec UT, Helferich WG. Estradiol increases ER-negative breast cancer metastasis in an experimental model. Clin Exp Metastasis 2013; 30: 711-721
• 130 Russo J, Russo IH.. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006; 102: 89-96
• 131 Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91: 421-430
• 132 Bray F, Loos AH, Oostindier M, Weiderpass E. Geographic and temporal variations in cancer of the corpus uteri: Incidence and mortality in pre- and postmenopausal women in Europe. Int J Cancer 2005; 117: 123-131
• 133 Carreau S, Bourguiba S, Lambard S, Galeraud-Denis I, Genissel C, Levallet J. Reproductive system: Aromatase and estrogens. Mol Cell Endocrinol 2002; 193: 137-144
• 134 Syed V, Ulinski G, Mok C, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 2002; 94: 617-629
• 135 Grow DR. Metabolism of endogenous and exogenous reproductive hormones. Obstet Gynecol Clin North Am 2002; 29: 425-436
• 136 Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. 2002. Lyon, France: International Agency for Research on Cancer Press;
• 137 Bouskine A, Nebout M, Mograbi B, Brücker-Davis F, Roger C, Fenichel P. Estrogens Promote Human Testicular Germ Cell Cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. Endocrinology 2008; 149: 565-573
• 138 Lambard S, Galeraud-Denis I, Saunders PTK, Carreau S. Human immature germ cells and ejaculated spermatozoa contain aromatase and estrogen receptors. J Mol Endocrinol 2004; 32: 279-289
• 139 Roger C, Lambard S, Bouskine A, Mograbi B, Chevallier D, Nebout M, Pointis G, Carreau S, Fenichel P. Estrogen-induced growth inhibition of human seminoma cells expressing estrogen receptor β and aromatase. J Mol Endocrinol 2005; 35: 191-199
• 140 Levin ER. Extranuclear steroid receptors are essential for steroid hormone actions. Annu Rev Med 2015; 66: 271-280
• 141 Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005; 14: 1262-1269
• 142 Tsai CJ, Cohn BA, Cirillo PM, Feldman D, Stanczyk FZ. Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: A longitudinal study in African-Americans and Caucasians (United States). Cancer Causes Control 2006; 17: 1237-1244
• 143 Barba M, Yang L, Schunemann HJ, Sperati F, Grioni S. Urinary estrogen metabolites and prostate cancer: A case-control study and meta-analysis. J Exp Clin Cancer Res 2009; 28: 135
• 144 Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D. Endogenous sex hormones and prostate cancer risk: A case-control study nested within the carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2003; 12: 1410-1416
• 145 Severi G, Morris HA, MacInnis RJ, English DR, Tilley W. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 86-91
• 146 Leung YK, Lam HM, Wu S, Song D. Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 2010; 17: 675-689
• 147 Imamov O, Morani A, Shim GJ, Omoto Y, Thulin-Andrsson C, Warner M, Gustafsson J-Å. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci USA 2004; 101: 9375-9380
• 148 Mishra S, Tai Q, Gu X, Schmitz J, Poullard A, Fajardo RJ, Mahalingam D, Chen X, Zhu X, Sun J-Z. Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer. Oncotarget 2015; 6: 44388-44402
• 149 Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000; 27: 39-66
• 150 Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE, Ho S-M. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 2004; 164: 2003-2012
• 151 Ji Q, Liu PI, Elshimali Y, Stolz A. Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR. Mol Cell Endocrinol 2005; 229: 103-110
• 152 Cheng J, Lee EJ, Madison LD, Lazennec G. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 2004; 566: 169-172
• 153 Baik CS, Eaton KD. Estrogen signaling in lung cancer: An opportunity for novel therapy. Cancers 2012; 4: 969-988
• 154 Chakraborty S, Ganti A, Marr A, Batra SK. Lung cancer in women: role of estrogens. Expert Rev Respir Med 2010; 4: 509-518
• 155 Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. Endocr Relat Cancer 2014; 5: 273-283
• 156 Giannitrapani L, Soresi M, La Spada E, Cervello M, D’Alessandro N, Montalto G. Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006; 1089: 228-236
• 157 Barzi A, Lenz AM, Labonte MJ, Lenz H-J. Molecular pathways: Estrogen pathway in colorectal cancer. Clin Cancer Res 2013; 19: 5842-5848
• 158 Gadducci A, Biglia N, Sismondi P, Genazzani AR. Breast cancer and sex steroids: Critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol 2005; 20: 343-360
• 159 Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract Suppl 2007; 61: 2051-2063
• 160 Olugbenga TA. Cellular Mechanisms of Oestrogen in Breast Cancer Development. Open Access J Sci Technol 2015 3 Article ID 101131
• 161 Maarten BC. The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention. Rev Urol 2005; 7 (Suppl. 03) S4-S10
• 162 Victor GV. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009; 9: 51-60
• 163 Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: Results from preclinical studies and a pilot phase II clinical trial. Br J Urol 2006; 97: 691-697
• 164 Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, Honma S, Evans DB, Hayashi S, Kondo T, Sasano H. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 2008; 14: 4417-4426
• 165 Santen RJ, Petroni GR, Fisch MJ, Myers CE, Theodorescu D, Cohen RB. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer 2001; 92: 2095-101
• 166 Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, Liao M, Chen Z, Lu S. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines. Lung Cancer 2012; 78: 193-200
• 167 Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23: 6931-6940
• 168 Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. A phase II study of letrozole. Cancer 2002; 95: 1864-1868
• 169 Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC. Long-term follow-up of the intergroup exemestane study. Clin Oncol 2017; 35: 2507-2514
• 170 Lakhani NJ, Venitz J, Figg WD, Sparreboom A. Pharmacogenetics of estrogen metabolism and transport in relation to cancer. Curr Drug Metab 2003; 4: 505-513
• 171 Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol 1996; 150: S259-S265
• 172 Lottering ML, Haag M, Seegers JC. Effects of 17 beta-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 1992; 52: 5926-5932
• 173 Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. Cancer Lett 2015; 356: 231-243
• 174 Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC. Endocrinedisrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009; 30: 293-342
• 175 Zhixiang X, Liu J, Wu X, Huang B, Pan X. Nonmonotonic responses to low doses of xenoestrogens: A review. Environ Res 2017; 155: 199-207
• 176 Caserta D, Maranghi L, Mantovani A, Marci R, Maranghi F, Moscarini M. Impact of endocrine disruptor chemicals in gynaecology. Hum Reprod Update 2008; 14: 59-72
• 177 Waring RH, Harris RM. Endocrine disrupters: A human risk. Mol Cell Endocrinol 2005; 244: 2-9
• 178 Bergman A, Heindel JJ, Kasten T, Kidd KA, Jobling S, Neira M, Zoeller RT, Becher G, Bjerregaard P, Bornman R. The impact of endocrine disruption: a consensus statement on the state of the science. Environ Health Perspect 2013; 121: 104-106
• 179 Pant N, Pant AB, Shukla M, Mathur N, Gupta YK, Saxena DK. Environmental and experimental exposure of phthalate esters: the toxicological consequence on human sperm. Hum Exp Toxicol 2011; 30: 507-514
• 180 Knez J. Endocrine-disrupting chemicals and male reproductive health. Reproductive BioMed Online 2013; 26: 440-448
• 181 Knez J, Kranvogl R, Breznik BP, Voncina E, Vlaisavljevic V. Urinary bisphenol A levels in men related to semen quality and embryo development after medically assisted reproduction. Fertil Steril 2013; 101: 215-236
• 182 Jeng HA. Exposure to Endocrine Disrupting Chemicals and Male Reproductive Health. Front Public Health 2014; 2: 1-12
• 183 Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE. Xenoestrogen action in prostate cancer: Pleiotropic effects dependent on androgen receptor status. Cancer Res 2005; 65: 54-65
• 184 Louis GM, Weiner JM, Whitcomb BW, Sperrazza R, Schisterman EF, Lobdell DT, Crickard K, Greizerstein H, Kostyniak PJ. Environmental PCB exposure and risk of endometriosis. Human Reprod 2005; 20: 279-285
• 185 Brouwers MM, Feitz WF, Roelofs LA, Kiemeney LA, de Gier R, Roeleveld N. Hypospadias: A transgenerational effect of diethylstilbestrol. Human Reprod 2006; 21: 666-669
• 186 Klip H, Verloop J, van Gool JD, Koster ME, Burger CW, Van Leeuwen FE. Hypospadias in sons of women exposed to diethylstilbestrol in utero: a cohort study. Lancet 2002; 359: 1102-1107
• 187 Palmer JR, Herbst AL, Noller KL, Boggs DA, Troisi R, Titus-Ernstoff L, Hatch EE, Wise LA, Strohsnitter WC, Hoover RN. Urogenital abnormalities in men exposed to diethylstilbestrol in utero: a cohort study. Environ Health 2009; 8: 1-6
• 188 Bibbo M. Follow-up study of male and female offspring of DES-exposed mothers. Obstetrics and Gynecology 1977; 49: 1-8
• 189 Verloop J, van Leeuwen FE, Helmerhorst TJM, van Boven HH, Rookus MA. Cancer risk in DES daughters. Cancer Causes Control 2010; 21: 999-1007
• 190 Palmer JR, Wise LA, Hatch EE, Troisi R, Titus-Ernstoff L, Strohsnitter W, Kaufman R, Herbst AL, Noller KL, Hyer M, Hoover RN. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1509-1514
• 191 Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Michels KB, Hunter DJ. In utero exposures and the incidence of endometriosis. Fertil Steril 2004; 82: 1501-1508
• 192 Main KM, Mortensen GK, Kaleva MM, Boisen KA, Damgaard IN, Chellakooty M, Schmidt IM, Suomi AM, Virtanen HE, Petersen DV, Andersson AM, Toppari J, Skakkebaek NE. Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. Environ Health Perspect 2006; 114: 270-276
• 193 Pant N, Manju S, Kumar Patel D, Shukla Y, Mathur N, Kumar Gupta Y. Correlation of phthalate exposures with semen quality. Toxicol Appl Pharmacol 2008; 231: 12-18
• 194 Rozati R, Bakshi HA, Baludu S, Sharma RS. Impact of high plasma concentrations of dioxin and polychlorinated biphenyls (PCBS) in South Indian women with endometriosis. Med J Islam World Acad Sci 2009; 17: 37-44
• 195 Main KM, Kiviranta H, Virtanen HE, Sundqvist E, Tuomisto JT, Tuomisto J, Vartiainen T, Skakkebaek NE, Toppari J. Flame retardants in placenta and breast milk and cryptorchidism in newborn boys. Environ Health Perspect 2007; 115: 1519-1526
• 196 Pesatori AC, Consonni D, Bachetti S, Zocchetti C, Bonzini M. BaccarelliA Bertazzi PA. Short- and long-term morbidity and mortality in the population exposed to dioxin after the Seveso accident. Industrial Health 2003; 41: 127-138
• 197 Eskenazi B, Warner M, Marks AR, Samuels S, Gerthoux PM, Vercellini P, Olive DL, Needham L, Patterson Jr D, Mocarelli P. Serum dioxin concentrations and age at menopause. Environ Health Perspect 2005; 113: 858-862
• 198 Leijs MM. Delayed initiation of breast development in girls with higher prenatal dioxin exposure; a longitudinal cohort study. Chemosphere 2008; 73: 999-1004
• 199 Simsa P, Mihalyi A, Schoeters G, Koppen G, Kyama CM, Den Hond EM, Fülöp V, D'Hooghe TM. Increased exposure to dioxin-like compounds is associated with endometriosis in a case-control study in women. Reprod Biomed Online 2010; 20: 681-688
• 200 Eskenazi B, Warner M, Samuels S, Young J, Gerthoux PM, Needham L, Patterson D, Olive D, Gavoni N, Vercellini P. Serum dioxin concentrations and risk of uterine leiomyoma in the Seveso Women’s Health Study. Am J Epidemiol 2007; 166: 79-87
• 201 Le TN, Johansson A. Impact of chemical warfare with agent orange on women's reproductive lives in Vietnam: a pilot study. Reprod Health Matters 2001; 9: 156-164
• 202 Guo YL. Yucheng: Health effects of prenatal exposure to polychlorinated biphenyls and dibenzofurans. Int Arch Occup Environ Health 2004; 77: 153-158
• 203 Staessen JA. Renal function, cytogenetic measurements and sexual development in adolescents in relation to environmental pollutants: A feasibility study of biomarkers. Lancet 2001; 357: 1660-1669
• 204 Li Y, Millikan RC, Bell DA, Cui L, Tse CK, Newman B, Conway K. Polychlorinated biphenyls, cytochrome P450 1A1 (CYP1A1) polymorphisms, and breast cancer risk among African American women and white women in North Carolina: A population-based case-control study. Breast Cancer Res 2005; 7: 12-18
• 205 Hauser R, Williams P, Altshul L, Calafat AM. Evidence of interaction between polychlorinated biphenyls and phthalates in relation to human sperm motility. Environ Health Perspective 2005; 113: 425-435
• 206 Gladen BC, Ragan NB., Rogan WJ. Pubertal growth and development and prenatal and lactational exposure to polychlorinated biphenyls and dichlorodiphenyldichloroethene. J Pediatr 2000; 136: 490-496
• 207 Andersen HR, Wohlfahrt-Veje CV, Jensen TK, Grandjean P, Skakkebaek NE, Katharina M. Prenatal pesticide exposure is associated with long term effects on endocrine function in children. . Poster presentation at Prenatal Programming and Toxicity. Miami Beach, Florida 2009; 7–10
• 208 Longnecker MP, Klebanoff MA, Brock JW, Zhou H, Gray KA, Needham LL. Maternal serum level of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene and risk of cryptorchidism, hypospadias, and polythelia among male offspring. AJE 2002; 155: 313-322
• 209 Hauser R, Altshul L, Chen Z, Ryan L, Overstreet J, Schiff I, Christiani DC. Environmental organochlorines and semen quality: Results of a pilot study. Environ Health Perspect 2002; 110: 229-233
• 210 Ouyang F, Perry MJ, Venners SA, Chen C, Wang B, Yang F, Fang Z, Zang T, Wang L, Xu X, Wang X., Serum DDT. age at menarche, and abnormal menstrual cycle length. Occup Environ Med 2005; 62: 878-884
• 211 Cooney MA, Buck Louis GM, Hediger ML, Vexler A, Kostyniak PJ. Organochlorine pesticides and endometriosis. ReprodToxicol 2010; 30: 365-369
• 212 Hsu PC, Huang W, Yao WJ, Wu MH, Guo YL, Lambert GH. Sperm changes in men exposed to polychlorinated biphenyls and dibenzofurans. JAMA 2003; 289: 2943-2944
• 213 Blanck HM, Marcus M. Tolbert Paige E, Rubin C, Henderson AK, Hertzberg VS, Zhang RH, Cameron L. Age at menarche and tanner stage in girls exposed in utero and postnatally to polybrominated biphenyl. Epidemiol 2000; 11: 641-647
• 214 Longnecker MP, Klebanoff MA, Brock JW, Guo X. Maternal levels of polychlorinated biphenyls in relation to preterm and small-for-gestational-age birth. Epidemiol 2005; 16: 641-647